Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

108.67 +1.87 (+1.75%)
Official Closing Price Updated: 4:10 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and... 
Via Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
The U.K. MHRA has approved Novo Nordisk's Wegovy (semaglutide) to prevent cardiovascular issues in overweight and obese adults with existing heart conditions. This new indication highlights Wegovy's... 
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool
Why Hims & Hers Heath Shares Are Surging Today
Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors. 
Via Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All. 
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
Here's My Top Growth Stock to Buy Right Now
Hims & Hers shares have multi-bagger growth potential over the years to come. 
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger. 
Via The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Skyrocketing demand for GLP-1 medications for weight loss is causing shortages, impacting type 2 diabetics. While some insurers are limiting off-label use, government agencies have yet to prioritize... 
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Eli Lilly's Tirzepatide approved by China's NMPA for long-term weight management, targeting adults with specific BMI criteria. 
Via Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
We could be headed to a volatile end to the year. The best way to protect yourself is to invest in A-rated stocks like these. 
Via InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
This biotech stock fits the profile of a potentially big winner to a T. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
Exposures US Equities
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
Ginkgo Bioworks has multiple, positive catalysts that can make the low valuation of Ginkgo Bioworks stock melt up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on. 
Via InvestorPlace
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
Novo Nordisk expresses disappointment over the Dutch Health Care Institute's advice against including Wegovy in the Netherlands' basic insurance, citing unclear health benefits and high costs. 
Via Benzinga
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. 
Via The Motley Fool
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On... 
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... 
Via Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Roche released early-stage data on its oral weight-loss drug. 
Via Investor's Business Daily
3 Hot Growth Stocks That Will Make You Forget About AMD
There are a number of hot growth stocks out there that can outdo AMD, even after its latest acquisition of Silo AI. 
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... 
Via Benzinga
3 Dow Jones Stocks to Buy at 52-Week Lows in July
The Dow Jones has rallied, similar to the other well-known market indices, but not all of its stocks are trading at all-time highs. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.